ContraFect Corporation (CFRXQ)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 56.88 Million USD | 20.41% |
| 2021 | 47.11 Million USD | 38.29% |
| 2020 | 34.07 Million USD | 23.01% |
| 2019 | 27.69 Million USD | -13.97% |
| 2018 | 32.19 Million USD | 22.06% |
| 2017 | 26.37 Million USD | -20.27% |
| 2016 | 33.08 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | 7.93 Million USD | -10.02% |
| 2023 Q3 | 6.63 Million USD | -16.33% |
| 2023 Q1 | 8.81 Million USD | 32.32% |
| 2022 Q1 | 15.94 Million USD | 13.52% |
| 2022 Q3 | 14.14 Million USD | -29.25% |
| 2022 Q4 | 6.66 Million USD | -52.87% |
| 2022 Q2 | 19.98 Million USD | 25.39% |
| 2022 FY | 56.73 Million USD | 20.41% |
| 2021 Q3 | 11.64 Million USD | 0.0% |
| 2021 FY | 47.11 Million USD | 38.29% |
| 2021 Q4 | 14.04 Million USD | 20.55% |
| 2020 FY | 34.07 Million USD | 23.01% |
| 2019 FY | 27.69 Million USD | -13.97% |
| 2018 FY | 32.19 Million USD | 22.06% |
| 2017 FY | 26.37 Million USD | -20.27% |
| 2016 FY | 33.08 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -4159.973% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -1028.292% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -92.498% |
| Nascent Biotech, Inc. | 2.22 Million USD | -2451.215% |
| Rebus Holdings, Inc. | 664 Thousand USD | -8467.62% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -52.699% |
| Qrons Inc. | 643.67 Thousand USD | -8738.128% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -14503.174% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 0.959% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -13592.389% |
| Skye Bioscience, Inc. | 13.54 Million USD | -319.921% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 34.448% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -1056.771% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -21636.09% |
| SQZ Biotechnologies Company | 85.61 Million USD | 33.556% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -1850.769% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -3687.805% |
| Mesoblast Limited | 5.9 Million USD | -863.894% |
| Marizyme, Inc. | 19.23 Million USD | -195.683% |
| Genus plc | 147.7 Million USD | 61.483% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -547.995% |
| Pharming Group N.V. | 225.49 Million USD | 74.771% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -2676.827% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -4140.558% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -582.204% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -1190.389% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -3747.095% |
| IMV Inc. | 37.7 Million USD | -50.862% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -1938.771% |
| MultiCell Technologies, Inc. | 567.42 USD | -10025806.736% |
| ONE Bio Corp. | 6.44 Million USD | -782.836% |
| Accustem Sciences Inc. | 3.74 Million USD | -1418.49% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 33.808% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -10594.185% |
| Q BioMed Inc. | 3.43 Million USD | -1555.373% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -130.18% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -2065.12% |
| Biomind Labs Inc. | 994.18 Thousand USD | -5622.192% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 42.727% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -3132.921% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -746.813% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -2951.379% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 227656.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -255.329% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -3000.057% |
| GB Sciences, Inc. | 1.42 Million USD | -3904.832% |
| Alpha Cognition Inc. | 9.7 Million USD | -486.146% |
| HST Global, Inc. | 140.9 Thousand USD | -40273.438% |
| CSL Limited | 3.44 Billion USD | 98.351% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -4957.205% |
| Halberd Corporation | 74.84 Thousand USD | -75912.132% |
| Enzolytics Inc. | 2.17 Million USD | -2510.177% |
| Agentix Corp. | 1.37 Million USD | -4047.166% |
| Resverlogix Corp. | 12.71 Million USD | -347.522% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -1458.301% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 96.29% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -5349.138% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -2265.512% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -3502.04% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -1570.759% |
| AVAX Technologies, Inc. | 7.31 Million USD | -678.207% |
| Zenith Capital Corp. | 8.94 Million USD | -536.129% |
| Genscript Biotech Corporation | 825.34 Million USD | 93.107% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -326454.159% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -2216.972% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -33069.688% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -2861.571% |
| Kadimastem Ltd | 2.41 Million USD | -2260.43% |
| Helix BioMedix, Inc. | 1.97 Million USD | -2784.788% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -423.502% |
| BioStem Technologies, Inc. | 22.97 Million USD | -147.615% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -31246.392% |
| LadRx Corporation | 3.81 Million USD | -1392.448% |
| Cell Source, Inc. | 4.32 Million USD | -1215.247% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -6060.085% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -6060.085% |
| NovAccess Global Inc. | 2.46 Million USD | -2206.223% |
| Affymax, Inc. | 39.38 Million USD | -44.44% |
| Itoco Inc. | 919.14 Thousand USD | -6089.352% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -1242.224% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -4983.914% |
| Mobile Lads Corp. | 554.54 Thousand USD | -10158.662% |
| CytoDyn Inc. | 18.05 Million USD | -215.035% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -225928.05% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -25749.472% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -3906.855% |
| SYBLEU INC | 160.87 Thousand USD | -35262.018% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -3032.102% |
| International Stem Cell Corporation | 5.27 Million USD | -979.283% |
| Bioxytran, Inc. | 3.82 Million USD | -1389.184% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -107967.703% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -279549.019% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -56.866% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -3416.007% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -7631.217% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -1728.64% |
| Neutra Corp. | 243.82 Thousand USD | -23232.281% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -225.881% |
| PureTech Health plc | 144.59 Million USD | 60.657% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -177.644% |
| IXICO plc | 4.7 Million USD | -1108.604% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -546.686% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 51.686% |
| CSL Limited | 3.89 Billion USD | 98.539% |
| Cellectis S.A. | 97.32 Million USD | 41.544% |